Strain specific proof - research into probiotics and why it matters
As research on the gut microbiome expands, the conversation has shifted from species-level probiotic recommendations to a far more precise, clinically relevant understanding of strain-specific effects. Strains within the same species can behave very differently—varying in survivability, adherence, immunomodulation, metabolite production, and clinical outcomes.
Below is a deep dive into the clinically studied probiotic strains commonly used in advanced digestive formulations, with a focus on their mechanistic actions and published human evidence. This review is designed to help practitioners make informed, evidence-aligned decisions in clinical practice.
Lactobacillus acidophilus LA85, DDS-1
Lactobacillus acidophilus is one of the most thoroughly researched probiotic species, known for producing lactic acid to lower intestinal pH, inhibiting pathogenic bacteria and improving the competitive landscape for beneficial microbes. Its ability to adhere to intestinal epithelial cells allows it to form a protective bio-layer that reduces pathogen colonisation and supports mucosal integrity.1
The LA85, DDS-1, and PTA-126813 strain profiles are particularly strong. Research shows it has high survival through the digestive tract, excellent adhesion to gut cells, potent antimicrobial activity, and an enhanced immunomodulatory function compared with other L. acidophilus strains.2
L. acidophilus interacts with endocannabinoid receptors in the gut, which modulates pain perception.
Clinical evidence
| Lactose intolerance | A randomised, double-blind, placebo-controlled crossover trial concluded that DDS-1 significantly reduced abdominal symptoms of lactose intolerance. It resulted in reduced bloating, cramping, and discomfort in adults with lactose intolerance.3 |
| IBS pain and symptom severity | A large randomised controlled trial involving 330 participants showed significant improvements in abdominal pain severity and overall IBS symptom burden with DDS-1. This is one of the largest IBS probiotic RCTs to date.4 |
| Antibiotic-associated diarrhoea |
The probiotic Lactobacillus acidophilus LA85 has shown antimicrobial and immune-supporting effects in lab studies, so researchers tested whether it could help prevent antibiotic-associated diarrhoea.5 In this randomised, double-blind, placebo-controlled study, 82 adults taking amoxicillin were given either LA85 or a placebo for 14 days. Researchers tracked how often antibiotic-associated diarrhoea occurred, how long diarrhoea lasted, stool consistency, digestive quality of life, and safety. The research showed that LA85 shortened the duration of antibiotic-associated diarrhoea.6 |
Lactobacillus rhamnosus LRa05, LGG
Lactobacillus rhamnosus strengthens the intestinal barrier, produces protective biofilms, and influences neurochemical pathways, particularly the modulation of GABA, a key inhibitory neurotransmitter involved in stress regulation and gut–brain communication. The LRa05, LGG, variant has demonstrated benefits for diarrhoeal conditions and tolerance to complex treatment regimens.7
Clinical evidence
| H. pylori eradication therapy | Research shows that supplementation with LRa05 can improve treatment tolerance, reduce GI side effects of eradication therapy and increase patient compliance. Given the length and intensity of H. pylori protocols, this strain is particularly valuable in supporting treatment adherence and comfort. |
Lacticaseibacillus casei LC89, UALc-03
L. casei has a high survivability rate in low pH environments and in bile salts, making it ideal for human gastrointestinal transit. The LC89/UALc-03 strain adheres strongly to intestinal cells, forming a barrier against pathogenic organisms.8
Clinical evidence
| Gastrointestinal relief in acute diarrhoea | A randomised controlled trial demonstrated the beneficial effect of L.casei LC89 on antibiotic resistance and antibiotic-associated diarrhoea.9 |
| Metabolic health | In high-fat diet type-2 diabetic mouse models, LC89 has been shown to improve glycaemic markers and modulate the gut microbiota. While human evidence is still building, this strain holds promise for future metabolic applications. 10 |
Bifidobacterium animalis subsp. lactis BLa80, BB-12
Bifidobacterium lactis has long been recognised for its ability to reinforce epithelial tight junctions, reduce intestinal permeability, and support immune balance. The BLa80/BB-12 group is among the most researched B. lactis groupings globally.11
Clinical evidence
| Antibiotic-associated disturbances (BB-12) | A randomised, double-blind, placebo-controlled trial involving 62 participants showed that this strain stabilised microbiome composition during antibiotic use and reduced functional disturbances. BB-12 has multiple human trials supporting its use during antibiotic therapy. 12 |
| Chronic constipation (BLa80) | A multicentre RCT demonstrated it to improve stool consistency and movement toward normal Bristol Stool Scale categories and improved bowel habits with bifidobacterium animalis subsp. lactis BLa80. 13 |
| Sleep quality (BLa80) | An 8-week randomised placebo-controlled trial showed significant improvements in sleep scores, likely via increased GABA production and gut–brain axis signalling. 14 |
| Glycaemic control in type-2 diabetes (BLa80) | A 12-week RCT involving 80 adults on metformin reported reductions in fasting blood glucose and favourable microbiota modulation. 15 |
Streptococcus thermophilus ST81, TH-4
S. thermophilus supports epithelial integrity and strengthens the mucosal barrier, an essential mechanisms in reducing gut permeability. It also produces lactic acid which helps maintain an acidic gut environment that inhibits potential pathogens.16
Clinical evidence
| Short-chain fatty acid production | It also contributes to SCFA production, particularly butyrate, supporting colonocyte health and exerting anti-inflammatory effects. Its role in enhancing gut resilience makes it valuable in formulations targeting gut barrier repair, immune balance, and dysbiosis. 17 |
Lactiplantibacillus plantarum Lp90, PPLP-217
L. plantarum is one of the most versatile probiotic species due to its wide antimicrobial spectrum, ability to support barrier function, and capacity to reduce oxidative stress within the gut. These mechanisms translate clinically to improvements in SIBO, gut dysbiosis, and inflammatory diseases.18
Clinical evidence
| Immunomodulatory |
It also has powerful immunomodulatory effects, helping to balance pro- and anti-inflammatory cytokines, and may be especially useful in chronic inflammatory bowel diseases such as Crohn’s and ulcerative colitis.19 The Lp90/PPLP-217 strain has also demonstrated protective effects in preventing and treating alcohol-induced liver damage, further expanding its therapeutic relevance.20 |
Conclusion
The evidence shows that strains matter. Two probiotics of the same species can behave entirely differently in the human body. The strains reviewed here demonstrate mechanisms that range from epithelial adhesion and barrier reinforcement to neurotransmitter modulation, SCFA production, and immune regulation.
You may be interested in reading our surveys
- Daily Multivitamin survey
- Menopause & gut health survey
- Gut health survey
- Bloating survey
- Skin health survey
- Stress survey
- Sleep survey
- Vaginal health survey
- PMS survey
References
Join our community of practitioners
Sign up for exclusive discounts for your clients, commission for you, free products to sample, priority access to latest research, expert webinars and events.
Join now